继续使用奥氮平与安慰剂对缓解期精神病性抑郁症患者复发的影响:STOP-PD II 随机临床试验
这项在4个学术医疗中心开展的36周随机临床试验纳入126例经舍曲林联合奥氮平急性治疗并达到缓解的精神病性抑郁症患者,比较继续奥氮平(n=64)与换用安慰剂(n=62)的复发风险。结果显示奥氮平组13例(20.3%)、安慰剂组34例(54.8%)复发(HR 0.25;95%CI 0.13-0.48;P<.001)。奥氮平对体重、腰围和总胆固醇的日变化率与安慰剂有显著差异,但该获益需与奥氮平的潜在不良反应(包括体重增加)相权衡。
要点
- 继续奥氮平组复发13例(20.3%),换用安慰剂组复发34例(54.8%),HR 0.25(95%CI 0.13-0.48;P<.001)。
- 奥氮平对体重(日变化率0.13 lb;95%CI 0.11-0.15)、腰围(0.009英寸;95%CI 0.004-0.014)和总胆固醇(0.29 mg/dL;95%CI 0.13-0.45)的日变化率与安慰剂显著不同。
- 低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、血糖和HbA1c水平的日变化率两组间无显著差异。
核心结论
- 在缓解期精神病性抑郁症患者中,继续舍曲林联合奥氮平与舍曲林联合安慰剂相比,36周内降低了复发风险,但该获益需与奥氮平的潜在不良反应(包括体重增加)相权衡。
研究设计与样本
- 36周随机临床试验,在4个学术医疗中心开展,研究时间为2011年11月至2017年6月,末次随访日期为2017年6月13日。
- 入组患者年龄18岁及以上,经舍曲林联合奥氮平急性治疗最多12周,达到精神病性症状缓解且抑郁症状缓解或接近缓解持续8周后进入试验。
- 共随机126例(平均[SD]年龄55.3岁[14.9岁];女性78例[61.9%]),继续奥氮平组n=64,换用安慰剂组n=62,所有参与者继续舍曲林。
- 114例(90.5%)完成试验;随机化时舍曲林中位剂量150 mg/d(IQR 150-200 mg/d),奥氮平中位剂量15 mg/d(IQR 10-20 mg/d)。
主要发现
- 奥氮平组13例(20.3%)与安慰剂组34例(54.8%)发生复发(HR 0.25;95%CI 0.13-0.48;P<.001)。
- 奥氮平对体重日变化率(0.13 lb;95%CI 0.11-0.15)、腰围日变化率(0.009英寸;95%CI 0.004-0.014)和总胆固醇日变化率(0.29 mg/dL;95%CI 0.13-0.45)的影响与安慰剂显著不同。
- 低密度脂蛋白胆固醇日变化率(0.04 mg/dL;95%CI -0.01-0.10)、高密度脂蛋白胆固醇日变化率(-0.01 mg/dL;95%CI -0.03-0.01)、甘油三酯日变化率(-0.153 mg/dL;95%CI -0.306-0.004)、血糖日变化率(-0.02 mg/dL;95%CI -0.12-0.08)和HbA1c日变化率(-0.0002 mg/dL;95%CI -0.0021-0.0016)两组间无显著差异。
临床怎么用
- 作者结论指出,缓解期精神病性抑郁症患者继续舍曲林联合奥氮平较舍曲林联合安慰剂降低36周复发风险,但该获益需与奥氮平的潜在不良反应(包括体重增加)相权衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Psychotic depression is a severely disabling and potentially lethal disorder. Little is known about the efficacy and tolerability of continuing antipsychotic medication for patients with psychotic depression in remission. OBJECTIVE: To determine the clinical effects of continuing antipsychotic medication once an episode of psychotic depression has responded to combination treatment with an antidepressant and antipsychotic agent. DESIGN, SETTING, AND PARTICIPANTS: Thirty-six week randomized clinical trial conducted at 4 academic medical centers. Patients aged 18 years or older had an episode of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks and met criteria for remission of psychosis and remission or near-remission of depressive symptoms for 8 weeks before entering the clinical trial. The study was conducted from November 2011 to June 2017, and the final date of follow-up was June 13, 2017. INTERVENTIONS: Participants were randomized either to continue olanzapine (n = 64) or switch from olanzapine to placebo (n = 62). All participants continued sertraline. MAIN OUTCOMES AND MEASURES: The primary outcome was risk of relapse. Main secondary outcomes were change in weight, waist circumference, lipids, serum glucose, and hemoglobin A1c (HbA1c). RESULTS: Among 126 participants who were randomized (mean [SD] age, 55.3 years [14.9 years]; 78 women [61.9%]), 114 (90.5%) completed the trial. At the time of randomization, the median dosage of sertraline was 150 mg/d (interquartile range [IQR], 150-200 mg/d) and the median dosage of olanzapine was 15 mg/d (IQR, 10-20 mg/d). Thirteen participants (20.3%) randomized to olanzapine and 34 (54.8%) to placebo experienced a relapse (hazard ratio, 0.25; 95% CI, 0.13 to 0.48; P < .001). The effect of olanzapine on the daily rate of anthropometric and metabolic measures significantly differed from placebo for weight (0.13 lb; 95% CI, 0.11 to 0.15), waist circumference (0.009 inches; 95% CI, 0.004 to 0.014), and total cholesterol (0.29 mg/dL; 95% CI, 0.13 to 0.45) but was not significantly different for low-density lipoprotein cholesterol (0.04 mg/dL; 95% CI, -0.01 to 0.10), high-density lipoprotein cholesterol (-0.01 mg/dL; 95% CI, -0.03 to 0.01), triglyceride (-0.153 mg/dL; 95% CI, -0.306 to 0.004), glucose (-0.02 mg/dL; 95% CI, -0.12 to 0.08), or HbA1c levels (-0.0002 mg/dL; 95% CI, -0.0021 to 0.0016). CONCLUSIONS AND RELEVANCE: Among patients with psychotic depression in remission, continuing sertraline plus olanzapine compared with sertraline plus placebo reduced the risk of relapse over 36 weeks. This benefit needs to be balanced against potential adverse effects of olanzapine, including weight gain. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01427608.
引用
- Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019. PMID: 31429896. doi:10.1001/jama.2019.10517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。